The risk of cancer in people with diabetes and chronic kidney disease

Germaine Wong, Sophia Zoungas, Serigne Lo, John Chalmers, Alan Cass, Bruce Neal, Mark Woodward, Vlado Perkovic, Paul Glasziou, Bryan Williams, Kirsten Howard, Jeremy Chapman, Jonathan Craig

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Background: Diabetes and chronic kidney disease (CKD)are both associated with an increased risk of cancer but it is unclear whetherdiabetes complicated by CKD further augments an individual's cancer risk. Theaim of our study was to determine the association of CKD [defined as anestimated glomerular filtration rate (eGFR) < 60 mL/min] with the overalland site-specific risks of incident cancers among individuals with Type 2diabetes.

     

    Methods: Cox proportional hazard regression models and competing risk analyseswere used to examine the univariate and multivariate adjusted associationsbetween reduced kidney function and the overall and site-specific risks ofcancer in participants enrolled in the Action in Diabetes and Vascular disease:Preterax and Diamicron MR controlled evaluation (ADVANCE) trial.

     

    Results: Over a median follow-up of 5.0 years, 700 malignant neoplasms occurredin the 11 140 (6.4%) participants. There was no increase in overall cancer risk[adjusted hazard ratio: 1.07 (95% confidence interval: 0.89-1.29, P = 0.50)] orsite-specific cancer risk for individuals with CKD (defined as eGFR < 60mL/min) compared to those without CKD at baseline. These results were robust tomultiple methods and thresholds used to estimate CKD.

     

    Conclusions: Mild to moderate CKD does not increase therisk of cancer in people with Type 2 diabetes. ADVANCE is registered withClincalTrial.gov (number NCT00145925).

    Original languageEnglish
    Pages (from-to)3337-3344
    Number of pages8
    JournalNephrology Dialysis Transplantation
    Volume27
    Issue number8
    DOIs
    Publication statusPublished - 2012

    Fingerprint

    Chronic Renal Insufficiency
    Neoplasms
    perindopril drug combination indapamide
    Gliclazide
    Glomerular Filtration Rate
    Vascular Diseases
    Proportional Hazards Models
    Type 2 Diabetes Mellitus
    Confidence Intervals
    Kidney

    Cite this

    Wong, G., Zoungas, S., Lo, S., Chalmers, J., Cass, A., Neal, B., ... Craig, J. (2012). The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 27(8), 3337-3344. https://doi.org/10.1093/ndt/gfs022
    Wong, Germaine ; Zoungas, Sophia ; Lo, Serigne ; Chalmers, John ; Cass, Alan ; Neal, Bruce ; Woodward, Mark ; Perkovic, Vlado ; Glasziou, Paul ; Williams, Bryan ; Howard, Kirsten ; Chapman, Jeremy ; Craig, Jonathan. / The risk of cancer in people with diabetes and chronic kidney disease. In: Nephrology Dialysis Transplantation. 2012 ; Vol. 27, No. 8. pp. 3337-3344.
    @article{4bed0854d453450f82b19205fd458737,
    title = "The risk of cancer in people with diabetes and chronic kidney disease",
    abstract = "Background: Diabetes and chronic kidney disease (CKD)are both associated with an increased risk of cancer but it is unclear whetherdiabetes complicated by CKD further augments an individual's cancer risk. Theaim of our study was to determine the association of CKD [defined as anestimated glomerular filtration rate (eGFR) < 60 mL/min] with the overalland site-specific risks of incident cancers among individuals with Type 2diabetes. Methods: Cox proportional hazard regression models and competing risk analyseswere used to examine the univariate and multivariate adjusted associationsbetween reduced kidney function and the overall and site-specific risks ofcancer in participants enrolled in the Action in Diabetes and Vascular disease:Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results: Over a median follow-up of 5.0 years, 700 malignant neoplasms occurredin the 11 140 (6.4{\%}) participants. There was no increase in overall cancer risk[adjusted hazard ratio: 1.07 (95{\%} confidence interval: 0.89-1.29, P = 0.50)] orsite-specific cancer risk for individuals with CKD (defined as eGFR < 60mL/min) compared to those without CKD at baseline. These results were robust tomultiple methods and thresholds used to estimate CKD. Conclusions: Mild to moderate CKD does not increase therisk of cancer in people with Type 2 diabetes. ADVANCE is registered withClincalTrial.gov (number NCT00145925).",
    author = "Germaine Wong and Sophia Zoungas and Serigne Lo and John Chalmers and Alan Cass and Bruce Neal and Mark Woodward and Vlado Perkovic and Paul Glasziou and Bryan Williams and Kirsten Howard and Jeremy Chapman and Jonathan Craig",
    year = "2012",
    doi = "10.1093/ndt/gfs022",
    language = "English",
    volume = "27",
    pages = "3337--3344",
    journal = "Nephrology Dialysis Transplantation",
    issn = "0931-0509",
    publisher = "Oxford University Press",
    number = "8",

    }

    Wong, G, Zoungas, S, Lo, S, Chalmers, J, Cass, A, Neal, B, Woodward, M, Perkovic, V, Glasziou, P, Williams, B, Howard, K, Chapman, J & Craig, J 2012, 'The risk of cancer in people with diabetes and chronic kidney disease', Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3337-3344. https://doi.org/10.1093/ndt/gfs022

    The risk of cancer in people with diabetes and chronic kidney disease. / Wong, Germaine; Zoungas, Sophia; Lo, Serigne; Chalmers, John; Cass, Alan; Neal, Bruce; Woodward, Mark; Perkovic, Vlado; Glasziou, Paul; Williams, Bryan; Howard, Kirsten; Chapman, Jeremy; Craig, Jonathan.

    In: Nephrology Dialysis Transplantation, Vol. 27, No. 8, 2012, p. 3337-3344.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - The risk of cancer in people with diabetes and chronic kidney disease

    AU - Wong, Germaine

    AU - Zoungas, Sophia

    AU - Lo, Serigne

    AU - Chalmers, John

    AU - Cass, Alan

    AU - Neal, Bruce

    AU - Woodward, Mark

    AU - Perkovic, Vlado

    AU - Glasziou, Paul

    AU - Williams, Bryan

    AU - Howard, Kirsten

    AU - Chapman, Jeremy

    AU - Craig, Jonathan

    PY - 2012

    Y1 - 2012

    N2 - Background: Diabetes and chronic kidney disease (CKD)are both associated with an increased risk of cancer but it is unclear whetherdiabetes complicated by CKD further augments an individual's cancer risk. Theaim of our study was to determine the association of CKD [defined as anestimated glomerular filtration rate (eGFR) < 60 mL/min] with the overalland site-specific risks of incident cancers among individuals with Type 2diabetes. Methods: Cox proportional hazard regression models and competing risk analyseswere used to examine the univariate and multivariate adjusted associationsbetween reduced kidney function and the overall and site-specific risks ofcancer in participants enrolled in the Action in Diabetes and Vascular disease:Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results: Over a median follow-up of 5.0 years, 700 malignant neoplasms occurredin the 11 140 (6.4%) participants. There was no increase in overall cancer risk[adjusted hazard ratio: 1.07 (95% confidence interval: 0.89-1.29, P = 0.50)] orsite-specific cancer risk for individuals with CKD (defined as eGFR < 60mL/min) compared to those without CKD at baseline. These results were robust tomultiple methods and thresholds used to estimate CKD. Conclusions: Mild to moderate CKD does not increase therisk of cancer in people with Type 2 diabetes. ADVANCE is registered withClincalTrial.gov (number NCT00145925).

    AB - Background: Diabetes and chronic kidney disease (CKD)are both associated with an increased risk of cancer but it is unclear whetherdiabetes complicated by CKD further augments an individual's cancer risk. Theaim of our study was to determine the association of CKD [defined as anestimated glomerular filtration rate (eGFR) < 60 mL/min] with the overalland site-specific risks of incident cancers among individuals with Type 2diabetes. Methods: Cox proportional hazard regression models and competing risk analyseswere used to examine the univariate and multivariate adjusted associationsbetween reduced kidney function and the overall and site-specific risks ofcancer in participants enrolled in the Action in Diabetes and Vascular disease:Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results: Over a median follow-up of 5.0 years, 700 malignant neoplasms occurredin the 11 140 (6.4%) participants. There was no increase in overall cancer risk[adjusted hazard ratio: 1.07 (95% confidence interval: 0.89-1.29, P = 0.50)] orsite-specific cancer risk for individuals with CKD (defined as eGFR < 60mL/min) compared to those without CKD at baseline. These results were robust tomultiple methods and thresholds used to estimate CKD. Conclusions: Mild to moderate CKD does not increase therisk of cancer in people with Type 2 diabetes. ADVANCE is registered withClincalTrial.gov (number NCT00145925).

    U2 - 10.1093/ndt/gfs022

    DO - 10.1093/ndt/gfs022

    M3 - Article

    VL - 27

    SP - 3337

    EP - 3344

    JO - Nephrology Dialysis Transplantation

    JF - Nephrology Dialysis Transplantation

    SN - 0931-0509

    IS - 8

    ER -